Int. J. Pharm. Sci. Rev. Res., ISSN: 0976 – 044X, 85(9) – September 2025; Article No. 26, Pages: 165-172 **DOI:** 10.47583/ijpsrr.2025.v85i09.026

Review Article

Rabies (*Lyssavirus rabies*) Conspectus: Its Life Cycle, Virology, Present Scenario Globally, along with India, Spread out & Treatment (Vaccination), Prevention Strategies

Yash Srivastav[1*], Jyotsana Shrivastava[2], Nutan Shrivastava[3], Madhaw Kumar[4]
[1]Shri Venkateshwara University, Gajraula, Uttar Pradesh, India.
[2]Dr. Rammanohar Lohia Avadh University, Uttar Pradesh, India.
[3]City Women's College, Jankipuram, Lucknow, Uttar Pradesh, India.
[4]Goel Institute of Pharmacy & Sciences, Lucknow, Uttar Pradesh, India.
***Corresponding author's E-mail:** neelashsrv76@gmail.com
***ORCID Id:** https://orcid.org/0009-0008-5017-6529

Received: 01-06-2025; **Revised:** 26-08-2025; **Accepted:** 05-09-2025; **Published online:** 20-09-2025.

ABSTRACT

Rabies, which means "madness" in Latin, is the root of the word. The genus name of the rabies virus, Lyssavirus, is derived from the Greek word lyssa, which means "violent" or "lud. The virus can infect most animals and spread the illness to people. Dogs are responsible for around 99 per cent of human rabies cases worldwide. Bats, monkeys, raccoons, foxes, skunks, cattle, wolves, coyotes, cats, and mongooses—typically the little Asian or yellow mongoose—are among the other animals that can infect people with rabies. A symptomatic rabid animal's saliva and nerves are typically where the virus is found. "Rabies is a dangerous zoonotic disease caused by the rabies virus, a neurotropic virus belonging to the Lyssavirus genus of the Rhabdoviridae family. Unlike most viruses, it travels through neurons in both people and animals rather than from the blood or lymphatic system. Animal bites, scratches, or licks of broken skin or mucous membranes are the primary ways that rabies, a deadly virus, is spread. Once rabies viruses have infected the central nervous system (brain and spinal cord, or CNS), the deadly disease has a roughly 100% fatality rate. Rabies viruses are helical in symmetry, and their infectious particles resemble sticks or bullets in morphology. In humans and other creatures, rabies is a virus that causes encephalitis. In the past, it was known as hydrophobia, or "fear of water," since those who suffer from it get anxious when given liquids to drink. Abnormal sensations at the location of exposure and fever are examples of early signs. This virus has an envelope and a negative-sense single-stranded linear RNA (ssRNA) genome of 11,615–11,966 nucleotides. An estimated 59,000 people worldwide die from rabies each year, making it a deadly zoonotic illness. In particular, when the rabies virus has spread to the central nervous system, the fatality rate is nearly 100%. The host immune system finds it challenging to fight off rabies viruses due to their unique life cycle and pathogenic mechanism. An efficient method of preventing rabies is vaccination, which includes prophylactic treatment before and after exposure. Despite high levels of awareness and vaccination uptake, India continues to lose over 5,700 lives to rabies each year, according to a nationwide survey conducted by the Indian Council of Medical Research –National Institute of Epidemiology (ICMR-NIE). Since a rule outlawed the slaughter of dogs in 2001, the number of stray dogs has significantly increased, making India the country with the highest risk of human rabies in the world. Puppy pregnancy syndrome (PPS), a type of collective hysteria, makes it difficult to effectively manage and cure rabies in India. Both male and female dog bite victims who have PPS start to believe that pups are growing inside of them and frequently turn to faith healers for assistance instead of the medical system. More than a third of all rabies deaths worldwide occur in India, where an estimated 20,000 people per year pass away from the disease. The aetiology, diagnosis, treatment, pathophysiology, and risk factors of the rabies virus are covered in this review article.

Keywords: Rabies, Pathophysiology, Epidemiology, Diagnosis, Treatment.

INTRODUCTION

The neurotropic rabies virus, also known as *Lyssavirus rabies*, infects humans and other animals. It can result in fever, hydrophobia, and aggression. Animal saliva can also spread rabies, and less frequently, human saliva can spread the disease. Like many other rhabdoviruses, the rabies virus has a very broad host range. Exposure to infected bears, domestic farm animals, groundhogs, weasels, and other wild carnivorans can also spread rabies. However, it is rare to find lagomorphs (like hares and rabbits) and tiny rodents (such chipmunks, gerbils, guinea pigs, hamsters, mice, rats, and squirrels) infected with rabies, and they are not known to spread the disease to humans. It is rarely necessary to prevent rabies from mouse, rat, or squirrel bites because these rodents are usually killed by any contact with a larger, rabid animal and would not be carriers. The Virginia opossum, a marsupial, is resistant to rabies but not immune to it because its internal body temperature is lower than that of the rabies virus, which prefers eutherian/placental mammals. Numerous mammalian species have been observed to contract it in the wild, and in vitro, it has been shown to infect birds as well as cell cultures from insects, reptiles, mammals, and birds[1]. More than 150 countries and every continent except Antarctica have reported cases of rabies. Rabies (RABV) and related viruses are zoonotic, neurotropic viruses that belong to the Lyssavirus genus and the family Rhabdoviridae. Clinical symptoms caused by these viruses are indistinguishable. Rabies is a global disease that affects a variety of mammals, including livestock, wildlife, dogs, cats, and bats. Through contaminated bites, open skin, or mucous membranes, as well as, in rare instances, organ donation, the RABV is spread by the saliva of infected animals. Since dog bites cause 99% of rabies cases, dogs are the main global reservoir for the disease. A rabies virus infection frequently starts with nebulous neurological symptoms and symptoms resembling a feverish viral disease. The infection has an almost 100% fatality rate once symptoms appear[2-4]. Clinicians can only offer palliative care in all but the most extreme circumstances to lessen the patient's agony and suffering before death. Patients often pass away at home because of the lack of access to healthcare in many areas. Human sickness can be effectively prevented by taking the right precautions both before and after being exposed to the rabies virus. Depending on the patient's preexposure vaccination status, postexposure prophylaxis includes cleaning the wound and receiving a series of rabies vaccinations, either with or without the introduction of human rabies immune globulin into the wound[5]. The One Health approach, which integrates environmental, veterinary, and medical disciplines to treat rabies in dogs and other animals that transmit the disease, including extensive animal vaccination programs, is the most economical way to prevent human rabies. Since ancient times, rabies has been a highly dreaded disease that affects both humans and animals because of its almost uniform death rate once symptoms start to show. Rabies manifests as a confused, feverish disease, often accompanied by pain and paresthesia at the wound site, after an incubation period that can last anywhere from a few days to many years. The neurological phase usually develops into encephalitic or paralytic rabies within two weeks, which is followed by coma. Usually, death happens two to three days after the coma starts. Reducing the patient's pain and suffering is usually the main goal of treatment once symptoms start. Many people pass away at home in nations with few resources. Although human rabies is uncommon in nations with abundant natural resources, it continues to be a major public health issue in areas with low resources, where it kills tens of thousands of people every year. Children are the main victims in regions without extensive preventive efforts, and the burden is greatest in Asia and Africa[6-7]. The rabies virus is a member of the Rhabdoviridae family's Lyssavirus genus and has a cylindrical shape. These viruses are enclosed and contain a negative-sense single-stranded RNA genome. The viral nucleoprotein firmly binds RNA in a ribonucleoprotein complex that contains the genetic information. Five genes in a highly conserved order are encoded by the virus's RNA genome. These genes produce the viral RNA polymerase (L), matrix protein (M), glycoprotein (G), phosphoprotein (P), and nucleoprotein (N). The lengths of the whole genome sequences vary from 11,615 to 11,966 nt. The proper hospital infection prevention and control programs, local public health authorities, or animal health authorities must be notified of any suspected or confirmed cases of rabies in humans or animals[8-9]. When a patient first presents, doctors frequently fail to diagnose rabies. Since palliative care is the only available treatment after symptoms manifest, rabies prevention is essential. Rabies postexposure prophylaxis (PEP) should be given immediately after exposure, particularly in cases of deep or repeated bites in densely nerved areas like the hands or locations near the central nervous system (CNS), such as the head and neck. PEP consists of cleaning the wound thoroughly, administering several rabies vaccines made from cell cultures, and, if the patient has never had rabies before, giving them human rabies immunoglobulin (HRIg). For anyone who is likely to be exposed to the RABV, such as veterinarians, frequent visitors, or citizens of endemic nations, preexposure prophylaxis, or PrEP, is available. Due to regional variations in animal carriers, rabies prevalence, and vaccine and HRIg availability, clinicians must be aware of local recommendations to identify the proper PEP. With assistance from the Centres for Disease Control (CDC), the Advisory Committee on Immunisation Practices (ACIP) created national human rabies prevention guidelines in the United States in 2008. In 2010, they were updated to lower the number of immunisations needed for PEP. Regionally specific guidelines are developed by state or local public health authorities. In order to increase programmatic viability, streamline vaccination schedules, and boost cost-effectiveness, the World Health Organisation (WHO) updated its 2010 rabies vaccine position paper in 2018. For structural, clinical, or patient reasons, the chance to administer suitable postexposure rabies prophylaxis may be lost. Particularly in situations of bat bites, patients might not be aware that a particular exposure poses a risk or may not even be aware that they were bitten. It's possible that clinicians don't know the proper pre- or postexposure treatment or the local rabies epidemiology where the bite happened. On a systemic level, missed treatment chances are caused by PEP's unavailability due to geographic constraints or its exorbitant cost. The most economical method of preventing dog-mediated human rabies globally is mass dog vaccination[10-13]. In partnership with the WHO, the United Against Rabies coalition, and other international animal and human health organisations, its 2017 Zero by 30 global strategic plan is to eradicate human rabies by 2030. Human rabies deaths can be completely avoided with timely and appropriate medical treatment. The most economical method of avoiding rabies in humans is to vaccinate dogs.



Figure 1: Rabies Virus

Every year, over 55,000 people, primarily in Asia and Africa, lose their lives due to a lack of knowledge about the importance of seeking medical attention after being bitten by a dog. 36% of rabies deaths worldwide occur in India, where the disease is prevalent. Although the exact number of rabies deaths in India is unknown, the current data indicates that the disease kills 18,000–20,000 people annually. Since child bites frequently go unnoticed and unreported, children under the age of 15 account for between 30 and 60 per cent of all rabies cases and deaths in India[14-16].

Signs and Symptoms

The initial signs of rabies, such as fever, headache, or overall weakness or discomfort, might be quite similar to those of the flu. Days may pass while these symptoms persist. In addition to discomfort or a prickling or itchy feeling at the bite site, symptoms of brain malfunction, anxiety, confusion, and agitation may develop within a few days. The condition starts to deteriorate when these progressive signs appear. The patient may develop hallucinations, sleeplessness, delirium, and aberrant conduct as the illness worsens. Additionally, the rabies virus may remain dormant in the body of its host for a long time before becoming active. The incubation time for this virus might range from a few weeks to several months. This is independent of the virus's particular form. The presence of microRNA, which inhibits viral replication in muscles, is most likely the cause of this lengthy incubation time. However, the virus has spread widely by the time the patient begins to show gastrointestinal symptoms and prodromal symptoms (fever, flu). Fever and exhaustion are examples of prodromal symptoms that appear in the first two to ten days following incubation. Additionally, they can affect the central nervous system and, gastrointestinal system, which can result in anorexia, nausea, vomiting, stomach discomfort, diarrhoea, and the respiratory system, which can cause sore throats and coughs. The symptoms of the central nervous system, which include headache, vertigo, anxiety, nightmares, depression, and more, are more common in certain situations. When the central nervous system slows down and malfunctions, neurological dysfunction ensues[17-18].

Rabies Life Cycle

The Rabies virus enters host cells via the endosomal transport pathway following receptor binding. The viral genome can enter the cytosol because of the low pH inside the endosome, which triggers the membrane fusion process. The glycoprotein G is essential to pathogenesis because it catalyses both receptor binding and membrane fusion (mutant virus cannot replicate without G proteins). Following its entry, the P-L polymerase (P is a necessary cofactor for the L polymerase) transcribes the viral genome to produce new viral protein. The viral polymerase cannot use free RNA as a template; it can only identify ribonucleoprotein. Protein M, which is necessary for virus budding and controls the proportion of mRNA production to replication, and cis-acting regions on the virus genome both control transcription. Polymerase activity transitions to replication later in infection to create full-length positive-strand RNA copies. To create new negative-strand RNA genomes, these complementary RNAs serve as templates[19]. Together with protein N, they make ribonucleoprotein, which can subsequently create new viruses. RABV and other viruses that resemble rabies are zoonotic, neurotropic, bullet-shaped RNA viruses that are members of the order Mononegavirales, family Rhabdoviridae, and genus Lyssavirus. With 14 species other than RABV known to cause rabies, enhanced surveillance and sequencing technology show that lyssaviruses are extremely diverse and constantly changing. While some lineages consist of only a few known isolates, others are well-known and widely distributed. After evolving through numerous host-switching events in dogs, bats, and other species, the RABV most likely descended from a bat progenitor. There are seven major RABV lineages around the globe, and each has several variations linked to particular species and regions.



Figure 2: The rabies virus's life cycle

In Europe, Africa, the Americas, and Asia, the most common lineage is seen in canines and animal species, including foxes, jackals, and skunks. In Latin America, numerous bat-associated lineages still infect domestic animals and humans with rabies. There are worries that the current HRIG and rabies vaccines may no longer be effective in preventing human rabies due to the ongoing genetic diversification of RABV and other Lyssaviruses[20,21].

Pathophysiology

The genome of the Lyssavirus contains a range of viruses, including the rabies virus and viruses that are genetically and anti-genetically similar to rabies. In addition to European bat viruses, these viruses include the Lagos Bat, Mokola, and Duvenhage viruses. Using additional anti-genetic characterisation, more than 350 rabies viruses specific to the Americas were identified. For these viruses, four phylogenetic groups were identified. This research also revealed more regions of circulation for the virus, including E. fuscus. When a virus spreads, RABV grows locally until it reaches a peripheral nerve synapse, usually a neuromuscular one. A neuronal cell adhesion molecule at the neural synapse, the nicotinic acetylcholine receptor, is essential for RABV cell entrance. The likelihood of effective transmission is increased by exposures in highly innervated tissues, like the hands and face. RABV moves proximally via retrograde axoplasmic flow after peripheral neuroinvasion. The dorsal root ganglia, which correlate to the nerves at the virus's entrance site, are where RABV enters[22]. Once the virus enters the dorsal root ganglia, local inflammation results in pain or paresthesia at the bite site, which is an early sign of rabies. A shorter incubation period is frequently the consequence of exposure in a proximal area, such as the head and neck. Once in the central nervous system, viral replication increases exponentially because of unchecked RABV replication, insufficient type I interferon production by glial cells, and a weak immune response. The motor neurons that innervate the RABV entry site determine the first location of brain infection. After CNS invasion, RABV spreads centrifugally by anterograde axonal transport, infecting different tissues. The main target is the salivary glands, and invasion of these organs results in sialorrhea, the characteristic foaming seen in clinical rabies. Death, nervous system failure, and encephalitis result from ongoing viral replication[23].



Figure 3: Pathophysiology of Human and Animal Rabies (Lyssavirus Rabies)

Histopathology

It seems that all of the current rabies viruses have changed throughout the past 1500 years. The Rabies virus comes in seven different genotypes. Genotype 1 (classical rabies) and, to a lesser degree, genotypes 5 and 6 (European bat lyssaviruses type-1 and -2) are responsible for the cases in Eurasia. As a result of European exploration and colonisation, genotype 1 emerged in Europe throughout the 17th century and spread to Asia, Africa, and the Americas. It seems that bat rabies has been in North America since 1281 AD (95% CI: 906-1577 AD). Due to a homologous recombination event that took place hundreds of years ago, the rabies virus seems to have evolved from Chiroptera (bats) to a species of Carnivora (skunks or raccoons). Autopsy reports show a diverse image of the RABV-infected brain[24]. The predominant histological image is one of encephalitis, which is challenging to differentiate from other viral encephalitides. Within the cytoplasm, although they only appear in 20% to 60% of cases, Negri bodies are a pathognomonic sign for rabies. Virion deposits are seen in the cytoplasm of the nerve by immunochemical staining. Negri bodies were discovered in the brain of a bat with peculiar tendencies in September 1931 by Trinidadian Joseph Lennox Pawan. Pawan made the initial discovery that humans and other animals may contract rabies from infected vampire bats in 1932. After a bite, the rabies virus first multiplies in muscle tissue before moving into neurons via their nerve terminals and into the nervous system. One of the most important stages of pathogenesis during a spontaneous infection is the retrograde axonal transfer of the Rabies virus to the central nervous system (CNS). Although it has been demonstrated that the Rabies virus's P protein binds to the dynein light chain protein DYNLL1, the precise biochemical mechanism underlying this transport is unknown. The virus spreads to other organs after leaving the central nervous system. High quantities of the virus are sent to the salivary glands in the tissues of the mouth and cheeks, which enables projectile salivation to spread the infection. Death may happen two days after the initial infection or five years later. However, a lot of this depends on the kind of animal serving as a reservoir. While strains of a species like the African yellow mongoose (Cynictis penicillata) may survive an infection asymptomatically for years, the majority of infected mammals pass out within weeks[25-27].

Epidemiology

Rabies Virus Distribution and Transmission Sources: Rabies viruses can infect any species, including dogs, cats, livestock, and wildlife, and they are found all over the planet except Antarctica. The majority of Lyssaviruses are found in chiropterans, or bats. However, mesocarnivores—animals that consume between 50% and 70% such as dogs, raccoons, mongooses, and skunks are the most prevalent reservoir species for the RABV. Other Lyssaviruses are endemic in many rabies-free nations. The great bulk of the rabies disease load is caused by the RABV. Even though humans can contract rabies from wild animals, domestic dogs—mostly unvaccinated domestic dogs-are the primary route of transmission in over 99% of human cases worldwide. On the other hand, over 90% of RABV is spread by wildlife, which leads to human cases in the US. Of the 3579 animal rabies cases recorded by the National Rabies Surveillance System in 2022, the most frequent carriers were bats (34.0%), raccoons (28.3%), skunks (18.4%), and foxes (27.5%). Over 90% of domestic animal rabies cases were in cats (6.2%), cattle (1.2%), and dogs (1.4%); almost all of these cases were unvaccinated. Areas where enzoonotic raccoon variant RABV spreads to other animal species are where the majority of animal rabies cases occur. Although infection can happen in rare cases, small rodents, rabbits, and hares are often not rabies reservoirs worldwide[28-30]. In the US, transmission to humans has never been reported (CDC). Beavers and groundhogs (woodchucks) are examples of large rodents that can act as reservoirs. In certain regions of Africa, rats are known to spread lyssaviruses. Rarely, highly concentrated virus aerosolisation in caves or labs or corneal, solid organ, or vascular transplantation can spread the virus. Otherwise, human-to-human transfer usually doesn't happen. *Clinical Presentation*: Humans can contract rabies, a zoonotic infection, by coming into contact with an infected animal's saliva through an abrasion, bite, open wound, conjunctiva, or mucous membranes, including genitalia. The risk of rabies transmission is significantly higher for bite exposures than for nonbite exposures. The normal incubation period for rabies is 20 to 90 days, but it can vary from a few days to several years. The density of nerve endings at the place of entry, the depth of the wound, the inoculum, the kind of mammal, and the immunocompetence of the host are some of the variables that affect the incubation period. Only a few dozen survivors — many of whom had severe neurological impairments — are reported in the literature following the onset of rabies symptoms. More than 150 nations and territories have rabies, a virus that can be prevented by vaccination. Dogs are responsible for up to 99 per cent of all human rabies transmissions and the great majority of human rabies deaths[31-33].

Diagnosis

Observation and Testing of Animals: Any stray domestic or wild animals, including bats, that may have exposed humans to rabies should be carefully captured, put to death right away, and sent for rabies testing. Families or patients shouldn't expose themselves to catching the animal. To preserve anatomical details for analysis, animal control officers only submit the animal's whole head or brain, including the brainstem. Bats and other tiny creatures are submitted whole. It is necessary to keep specimens in a refrigerator. Given the well-established incubation time for rabies in cats, dogs, and ferrets, experts frequently advise a 10-day monitoring period. A rabies antigen level may be necessary, and any animal exhibiting symptoms must be examined by a veterinarian who will swiftly notify public health authorities of the situation. When an animal exhibits symptoms of rabies, it must be put down and sent for examination. Through the CDC or other state or university facilities, state or municipal public health departments can help get the necessary laboratory testing. The turnaround period for submitted specimens is three days, according to the CDC. *Rabies Disease:* Laboratory testing is essential for early identification of rabies because it is a rare disease with first symptoms that frequently resemble those of other neurological conditions. Electrolyte measurements, cultures, and a complete blood count are all part of routine laboratory evaluations. Analysis of cerebrospinal fluid (CSF) usually yields nonspecific signs, like pleocytosis and increased protein, that are diagnostic of encephalitis[34]. Myocarditis, heart block, ST-elevation syndrome, or heart failure may be detected by an ECG or other cardiac testing. In cases of rabies, imaging, including neuroimaging, is usually normal; nonetheless, it may exclude other illnesses from the differential diagnosis. When a patient is upset, getting neuroimaging can be difficult. Specific testing of several samples is necessary to confirm a rabies diagnosis and differentiate it from other viral diseases. The CDC requires four materials for a conclusive antemortem diagnosis: skin biopsies from the nape of the neck, CSF, saliva, and serum. At least ten hair follicles and one cutaneous nerve at the base of each follicle must be present in the full-thickness punch biopsy. Samples must be sent right away and kept free of extra fluid or preservatives. The

CDC must receive samples that are refrigerated within three days and samples that are stored at -20°C or lower within twenty-one days. The normal turnaround time is seven days, but for human or animal species, it can be shortened to less than three days. Commercial testing may also be offered by state health departments. *Rabies Exposure:* Unless the extent of the wound suggests otherwise, laboratory, radiography, and other testing are not usually necessary to evaluate a patient for potential rabies exposure[35-38]. Routine virus-neutralising antibody testing is not necessary for healthy patients completing PrEP or PEP; however, the CDC advises immunocompromised patients to undergo post-PrEP and post-PEP antibody testing. Within one to two weeks after a patient has received dubious rabies biologicals abroad, antibody testing employing rapid fluorescence focus inhibition testing (RFFIT) can also be useful in determining the course of treatment. The CDC states that an antibody level that fully neutralises a viral challenge at a serum dilution of 1:5 is the lowest permissible level. A titer of more than 0.5 IU/mL is advised by the WHO. Finding a suitable lab for RFFIT might be aided by state and local health departments[39].

Rabies Management and Treatment

Stabilising the trimeric pre-fusion form of the rabies virus glycoprotein (RABV-G), the protein's most immunogenic shape, is the main goal of recent studies. This form's stability is increased by mutations such as H270P and H261L, which increase its immunogenic potency. This strategy seeks to address the continuous demand for rabies prevention worldwide by creating vaccinations that are more affordable and offer more protective coverage. It's interesting to note that the SAD-B19 complex, which contains the L-P protein, was used to make the rabies virus vaccine and was also used to create the SARS-CoV-2 vaccine. A novel vaccination that was proven to be effective in guarding against COVID-19 was created by inserting the S1 protein from SARS-CoV-2 into the rabies virus vaccine vector. FiloRab1, a vaccine against Ebola made from the rabies virus, is 100% efficacious in nonhuman primates. *Vaccinations against rabies:* Vaccines against rabies are quite safe and well-tolerated. The administration of the rabies vaccine as PEP is not contraindicated due to the high rabies death rate[40]. Global experts believe that the rabies vaccine is safe to use during pregnancy and lactation; scant data indicate that there is no rise in fetal abnormalities, preterm births, or spontaneous abortions. Two rabies vaccines have been approved by the US Food and Drug Administration (FDA): the pure chick embryo cell vaccine (PCECV) (RabAvert®) and the human diploid cell vaccine (HDCV) (Imovax®). There are several rabies vaccines available and in use throughout the world that are not FDA-approved and may or may not be WHO-recommended. Similar to the US, the WHO suggests PCECV or HDCV[41]. The WHO recommends against producing or using any vaccinations that are derived from nerves. Adsorbed rabies vaccination (RVA) is not advised. RVA and nerve-cell-derived vaccinations are less effective and more likely to cause side effects. More than 2.5 IU of rabies antigen, diluted at the point of care in 1 mL of diluent, are present in HDCVs and PCECVs. Despite the WHO's suggestion for ID schedules that save time and vaccine, the United States and many other nations still solely advise IM vaccination administration. When a patient has never had rabies immunity before, rabies immunoglobulin (RIg) offers passive immunity for rabies PEP. Three HRIg products—HyperRabTM S/D, HyperRabTM, and Imogam® Rabies-HT—that use plasma from hyperimmune people are licensed in the US. In and around the wound, all are given intramuscularly. Since HyperRabTM is the only RIg with a concentration of 300 IU/mL (all others have a concentration of 150 IU/mL), a smaller volume is needed for administration. Several more HRIg formulations, all at 150 IU/L (except those that have a 300 IU/L product available), are licensed in different nations. Equine rabies immunoglobulin (ERIg) is used in some nations because it is more readily available or less expensive. In order to treat anaphylactic reactions, clinicians need to be prepared. Adverse responses are more likely to occur with ERIg (0.8% to 6%); however, they are generally milder than with HRIg. The WHO promotes the use of monoclonal antibodies over RIg where they are available, and India manufactures and licenses two potent rabies monoclonal antibody products. Wound care: Regardless of the possibility of rabies, the first line of treatment for any wound brought on by a bite, contact with saliva, or tissue is thorough, gentle washing. According to research on animals, washing with soap and water for at least fifteen minutes lowers the risk of rabies by thirty per cent. To prevent more tissue damage, caution should be exercised[42-44]. The next step should be irrigation with a virucidal chemical, like povidone-iodine, if one is available. Those with immunocompromising disorders need to receive proper wound care. Immediate wound care and rabies vaccine, with or without rabies immune globulin (RIg), must be given as soon as feasible after exposure in order to treat a patient who is at risk of rabies transmission. Depending on risk tolerance, financial resources, and the accessibility of rabies biologicals in a given area, suggested regimens differ globally in terms of the quantity and method of rabies vaccine delivery as well as the types of wounds that need RIG. The requirement for doctors to follow local procedures is highlighted by the differences in treatment guidelines between the United States and Canada for possible bat exposure. Unless there is reason to think that no contact occurred, the CDC recommends rabies PEP in every situation. Rabies vaccine: Adults should receive IM rabies vaccinations in the deltoid, while children should receive them in the deltoid or anterolateral thigh. IM vaccinations should never be given in the gluteal or buttock regions. All age groups can receive WHO-recommended ID vaccinations in the suprascapular, anterolateral thigh, or deltoid regions. For individuals who have never received a rabies vaccination, the CDC advises giving the vaccine on days 0, 3, 7, and 14 following exposure. On day 28, patients with immunocompromising disorders ought to receive their fifth dose. In order to minimise disruption for patients who frequently travel large distances for treatment, the WHO recommends both ID and IM immunisation regimens. The vaccination should be given in various locations and limbs for multisite regimens. Two intradermal sites were used on days 0–3, and 7. 1-site instant messaging (IM) on days 0, 3, 7, and 14–28 (Essen regimen, same as US regimen). Day 0: 2-site IM; Days 7 and 21: 1-site IM (Zagreb regimen)[45-46].



Figure 4: Procedure for Rabies Virus Therapy or Vaccinations

DISCUSSION AND CONCLUSION

An overview of the rabies virus is given in our review papers, which also address its pathophysiology, epidemiology, diagnostics, alternate therapies (such as vaccination), and many causes. Our findings suggest that, despite the fact that the rabies virus can be treated with neurological drugs and other treatments, additional clinical studies are required due to its intricacy. The rabies virus needs to be treated with more randomized controlled trials. A preliminary rabies virus examination is something we intend to do in the future. With the help of our colleagues, more accurate information on the rabies virus and its treatment will be provided by future counseling-based research in our state or nation, which will evaluate patients' physical and mental health.

Ethical Statement

A pharmacist must behave honorably and truthfully. A pharmacist avoids behaviors that compromise their commitment to acting in the best interests of their patients, such as discriminatory actions, incorrect behavior, and adverse working conditions that impair judgment. A pharmacist maintains their level of proficiency.

ACKNOWLEDGEMENT

The authors would like to thank **Shri Venkateshwara University, Gajraula, Uttar Pradesh, India, Dr. Rammanohar Lohia Avadh University, Uttar Pradesh, India, City Women's College, Jankipuram, Lucknow, Uttar Pradesh, India & Goel Institute of Pharmacy & Sciences, Lucknow, U.P., India.** Lucknow, Uttar Pradesh, India, for extending their facilities.

CONFLICT OF INTEREST

The authors attest that they are free of any known financial or personal conflicts of interest that would taint the findings of this study.

INFORMED CONSENT

Using websites, review articles, and other sources to produce research content.

REFERENCES

1. Lafon, M. Evasive strategies in rabies virus infection. Adv. Virus Res. 2011;79:33–53.

2. Gaudin, Y.; Tuffereau, C.; Durrer, P.; Brunner, J.; Flamand, A.; Ruigrok, R. Rabies virus-induced membrane fusion. Mol. Membr. Biol. 1999;16:21–31.

3. Tarantola A. Four Thousand Years of Concepts Relating to Rabies in Animals and Humans, Its Prevention and Its Cure. Trop Med Infect Dis. 2017 Mar 24;2(2):29-35.

4. Lacy M, Phasuk N, Scholand SJ. Human Rabies Treatment-From Palliation to Promise. Viruses. 2024 Jan 22;16(1):70-75.

5. Fisher CR, Streicker DG, Schnell MJ. The spread and evolution of rabies virus: conquering new frontiers. Nat Rev Microbiol. 2018 Apr;16(4):241-255.

6. Pattanaik A, Mani RS. WHO's new rabies recommendations: implications for high incidence countries. Curr Opin Infect Dis. 2019 Oct;32(5):401-406.

7. Hwang GS, Rizk E, Bui LN, Iso T, Sartain EI, Tran AT, Swan JT. Adherence to guideline recommendations for human rabies immune globulin patient selection, dosing, timing, and anatomical site of administration in rabies postexposure prophylaxis. Hum Vaccin Immunother. 2020;16(1):51-60.

8. Whitehouse ER, Mandra A, Bonwitt J, Beasley EA, Taliano J, Rao AK. Human rabies despite post-exposure prophylaxis: a systematic review of fatal breakthrough infections after zoonotic exposures. Lancet Infect Dis. 2023 May;23(5):e167-e174.

9. Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, Meltzer MI, Dhankhar P, Vaidya SA, Jenkins SR, Sun B, Hull HF., Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC). Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2008 May 23;57(RR-3):1-28.

10. Yahiaoui F, Kardjadj M, Laidoudi Y, Medkour H, Ben-Mahdi MH. The epidemiology of dog rabies in Algeria: Retrospective national study of dog rabies cases, determination of vaccination coverage and immune response evaluation of three commercial used vaccines. Prev Vet Med. 2018 Oct 01;158:65-70.

11. Broban A, Tejiokem MC, Tiembré I, Druelles S, L'Azou M. Bolstering human rabies surveillance in Africa is crucial to eliminating canine-mediated rabies. PLoS Negl Trop Dis. 2018 Sep;12(9):e0006367.

12. World Health Organization Rabies vaccines: WHO position paper, April 2018 - Recommendations. Vaccine. 2018 Sep 05;36(37):5500-5503.

13. Changalucha J, Hampson K, Jaswant G, Lankester F, Yoder J. Human rabies: prospects for elimination. CAB Rev. 2021;16.

14. Ma X, Bonaparte S, Corbett P, Orciari LA, Gigante CM, Kirby JD, Chipman RB, Fehlner-Gardiner C, Thang C, Cedillo VG, Aréchiga-Ceballos N, Rao A, Wallace RM. Rabies surveillance in the United States during 2021. J Am Vet Med Assoc. 2023 Jul 01;261(7):1045-1053.

15. Elmore SA, Chipman RB, Slate D, Huyvaert KP, VerCauteren KC, Gilbert AT. Management and modeling approaches for controlling raccoon rabies: The road to elimination. PLoS Negl Trop Dis. 2017 Mar;11(3):e0005249.

16. Badrane H, Tordo N. Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders. J Virol. 2001 Sep;75(17):8096-104.

17. Gibbons K, Dvoracek K. Rabies postexposure prophylaxis: What the U.S. emergency medicine provider needs to know. Acad Emerg Med. 2023 Nov;30(11):1144-1149.

18. Liu C, Cahill JD. Epidemiology of Rabies and Current US Vaccine Guidelines. R I Med J (2013). 2020 Aug 03;103(6):51-53.

19. Ma X, Boutelle C, Bonaparte S, Orciari LA, Condori RE, Kirby JD, Chipman RB, Fehlner-Gardiner C, Thang C, Cedillo VG, Aréchiga-Ceballos N, Nakazawa Y, Wallace RM. Rabies surveillance in the United States during 2022. J Am Vet Med Assoc. 2024 Nov 01;262(11):1518-1525.

20. Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, Barrat J, Blanton JD, Briggs DJ, Cleaveland S, Costa P, Freuling CM, Hiby E, Knopf L,

Leanes F, Meslin FX, Metlin A, Miranda ME, Müller T, Nel LH, Recuenco S, Rupprecht CE, Schumacher C, Taylor L, Vigilato MA, Zinsstag J, Dushoff J., Global Alliance for Rabies Control Partners for Rabies Prevention. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015 Apr;9(4):e0003709.

21. Lin Y, Fang K, Zheng Y, Wang HL, Wu J. Global burden and trends of neglected tropical diseases from 1990 to 2019. J Travel Med. 2022 May 31;29(3)

22. Feige L, Zaeck LM, Sehl-Ewert J, Finke S, Bourhy H. Innate Immune Signaling and Role of Glial Cells in Herpes Simplex Virus- and Rabies Virus-Induced Encephalitis. Viruses. 2021 Nov 25;13(12)

23. Potratz M, Zaeck LM, Weigel C, Klein A, Freuling CM, Müller T, Finke S. Neuroglia infection by rabies virus after anterograde virus spread in peripheral neurons. Acta Neuropathol Commun. 2020 Nov 23;8(1):199.

24. Guo X, Zhang M, Feng Y, Liu X, Wang C, Zhang Y, Wang Z, Zhang D, Guo Y. Transcriptome analysis of salivary glands of rabies-virus-infected mice. Front Microbiol. 2024;15:1354936.

25. Stein LT, Rech RR, Harrison L, Brown CC. Immunohistochemical study of rabies virus within the central nervous system of domestic and wildlife species. Vet Pathol. 2010 Jul;47(4):630-3.

26. Alexander B, Lopez-Lopez JP, Saldarriaga C, Ponte-Negretti CI, Lopez-Santi R, Perez GE, Del Sueldo M, Lanas F, Liblik K, Baranchuk A. Rabies and the Heart. Cardiol Res. 2021 Apr;12(2):53-59.

27. Jones NJ, Jarvis JA, Appler KA, Davis AD. Detection of Rabies IgG and IgM Antibodies Using the Rabies Indirect Fluorescent Antibody Test. J Vis Exp. 2024 Jan 19;(203)

28. Wadhwa A, Wilkins K, Gao J, Condori Condori RE, Gigante CM, Zhao H, Ma X, Ellison JA, Greenberg L, Velasco-Villa A, Orciari L, Li Y. A Pan-Lyssavirus Taqman Real-Time RT-PCR Assay for the Detection of Highly Variable Rabies virus and Other Lyssaviruses. PLoS Negl Trop Dis. 2017 Jan;11(1):e0005258.

29. Moore SM. Challenges of Rabies Serology: Defining Context of Interpretation. Viruses. 2021 Jul 31;13(8):52-57.

30. Kim PK, Ahn JS, Kim CM, Seo JM, Keum SJ, Lee HJ, Choo MJ, Kim MS, Lee JY, Maeng KE, Shin JY, Yi KS, Osinubi MOV, Franka R, Greenberg L, Shampur M, Rupprecht CE, Lee SY. A broad-spectrum and highly potent human monoclonal antibody cocktail for rabies prophylaxis. PLoS One. 2021;16(9):e0256779.

31. Tarantola A, Tejiokem MC, Briggs DJ. Evaluating new rabies post-exposure prophylaxis (PEP) regimens or vaccines. Vaccine. 2019 Oct 03;37 Suppl 1:A88-A93.

32. Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, Lett SM, Levis R, Meltzer MI, Schaffner W, Cieslak PR., Centers for Disease Control and Prevention (CDC). Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep. 2010 Mar 19;59(RR-2):1-9.

33. Jin J. Rabies. JAMA. 2023 Jan 24;329(4):350-9.

34. Cliquet, F.; Picard-Meyer, E.; Robardet, E. Rabies in Europe: What are the risks? Expert Rev. Anti-Infect. Ther. 2014;12:905–908.

35. Rupprecht, C.E.; Hanlon, C.A.; Hemachudha, T. Rabies re-examined. Lancet Infect. Dis. 2002;2:327–343.

36. George, D.B.; Webb, C.T.; Farnsworth, M.L.; O'Shea, T.J.; Bowen, R.A.; Smith, D.L.; Stanley, T.R.; Ellison, L.E.; Rupprecht, C.E. Host and viral ecology determine bat rabies seasonality and maintenance. Proc. Natl. Acad. Sci. USA 2011;108:10208–10213.

37. Sabeta, C.T.; Marston, D.A.; McElhinney, L.M.; Horton, D.L.; Phahladira, B.M.N.; Fooks, A.R. Rabies in the African Civet: An Incidental Host for Lyssaviruses? Viruses 2020;12: 368.

38. Gilbert, A.T. Rabies virus vectors and reservoir species. Rev. Sci. Tech. 2018;37:371–384.

39. Kumar, A.; Bhatt, S.; Kumar, A.; Rana, T. Canine Rabies: An Epidemiological Significance, Pathogenesis, Diagnosis, Prevention, and Public Health Issues. Comp. Immunol. Microbiol. Infect. Dis. 2023;97:101992.

40. Mbilo, C.; Coetzer, A.; Bonfoh, B.; Angot, A.; Bebay, C.; Cassamá, B.; De Benedictis, P.; Ebou, M.H.; Gnanvi, C.; Kallo, V.; et al. Dog rabies control in West and Central Africa: A review. Acta Trop. 2021;224:105459.

41. Fehlner-Gardiner, C.; Gongal, G.; Tenzin, T.; Sabeta, C.; De Benedictis, P.; Rocha, S.M.; Vargas, A.; Cediel-Becerra, N.; Gomez, L.C.; Maki, J.; et al. Rabies in Cats-An Emerging Public Health Issue. Viruses 2024;16:1635.

42. Walker, P.J. International Committee on Taxonomy of Viruses Genus (ICTV). Book: Rhabdoviridae, Subfamily: Alpharhabdovirinae, Genus: Lyssavirus. ICTV Virus Taxonomy Profile: Rhabdoviridae. J. Gen. Virol. 2022;103:001689. Available online: https://ictv.global/report/chapter/rhabdoviridae/rhabdoviridae/lyssavirus (accessed on 1 October 2024).

43. Tordo, N.; Bahloul, C.; Jacob, Y.; Jallet, C.; Perrin, P.; Badrane, H. Rabies: Epidemiological tendencies and control tools. Dev. Biol. 2006;125:3–13.

44. Leopardi, S.; Dacheux, L.; Serra-Cobo, J.; Ábrahám, Á.; Baji´c, B.; Bourhy, H.; Bücs, S.-L.; Budinski, I.; Castellan, M.; Drzewniokova, P.; et al. European Distribution and Intramuscularpathogenicity of Divergent Lyssaviruses West Caucasian Bat Virus and Lleida Bat Lyssavirus. iScience 2025;28:111738.

45. Ng, W.M.; Fedosyuk, S.; English, S.; Augusto, G.; Berg, A.; Thorley, L.; Haselon, A.S.; Segireddy, R.R.; Bowden, T.A.; Douglas, A.D. Structure of trimeric pre-fusion rabies virus glycoprotein in complex with two protective antibodies. Cell Host Microbe. 2022;30:1219–1230.e7.

46. Hellgren, F.; Cagigi, A.; Arcoverde Cerveira, R.; Ols, S.; Kern, T.; Lin, A.; Eriksson, B.; Dodds, M.G.; Jasny, E.; Schwendt, K.; et al. Unmodified rabies mRNA vaccine elicits high cross-neutralizing antibody titers and diverse B cell memory responses. Nat. Commun. 2023;14:3713-8.